MedTrace Logo

Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction

NCT03033537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-01-27

No results posted yet for this study

Summary

Introduction: Erectile dysfunction is a common condition with a significant effect on quality of life. Verapamil is calcium channel blocker of the phenyl alkylamine class which relaxes the tone of the smooth muscles lining blood vessels, leading to their dilatation.

Conditions

Interventions

DRUG

Verapamil

Local treatment of erectile dysfunction

Sponsors & Collaborators

  • Adam International Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2016-01-01
Completion
2016-01-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033537 on ClinicalTrials.gov